Cellectar Biosciences, Inc. (CLRB): R&D Expense
$11.50M
Year ended 2025-12-31
$13.25M
Trailing 12 months to 2026-06-30
-14.3%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.50M | -56.0% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $26.14M | -4.1% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $27.27M | +49.3% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $18.27M | n/c | 2024-10-29, From 2022-01-01 |
| 2021-12-31 | $17.59M | +73.4% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $10.14M | +12.7% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $9.00M | +31.6% | 2021-03-02, From 2019-01-01 |
| 2018-12-31 | $6.84M | -27.8% | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | $9.47M | +99.3% | 2019-02-26, From 2017-01-01 |
| 2016-12-31 | $4.75M | -7.9% | 2018-03-21, From 2016-01-01 |
| 2015-12-31 | $5.16M | -13.5% | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | $5.96M | -13.1% | 2016-10-20, From 2014-01-01 |
| 2013-12-31 | $6.86M | +33.9% | 2015-05-20, From 2013-01-01 |
| 2012-12-31 | $5.12M | +42.3% | 2014-03-19, From 2012-01-01 |
| 2011-12-31 | $3.60M | +20.6% | 2013-03-28, From 2011-01-01 |
| 2010-12-31 | $2.98M | n/a | 2012-03-09, From 2010-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $11.50M | -56.0% |
| Cingulate Inc. (CING) | 2025-12-31 | $9.77M | +3.5% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $43.0K | -99.5% |
| Biovie Inc. (BIVI) | 2026-06-30 | $13.96M | +50.7% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $11.71M | -48.9% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $7.04M | -24.8% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.29M | n/a |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $10.29M | -44.9% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $5.07M | -20.7% |
Compare CLRB, CING, SYBX, BIVI side by side · Screen every company in Pharmaceutical Preparations ↗